Search

Background: Current diagnostic methods for Schistosoma japonicum infection are insensitive for low-density infections. Therefore, a new diagnostic assay based on recombinase polymerase amplification (RPA) technology was established and assessed for field applification.Methods: The S.japonicum RPA assay was developed to target highly repetitive retrotransposon SjR2 gene of S japonicum, and its sensitivity and specificity were assessed by serial dilution of S. japonicum genomic DNA and other related worm genomic DNA respectively. The RPA diagnostic validity was first evaluated in 60 fecal samples from healthy people and patients, and then compared with other diagnostic tests in 200 high-risk individuals living in endemic areas.Results: The real time RPA assay could detect 0.9 fg S. japonicum DNA within 15 min and distinguish S. japonicum from other worms. The validity analysis of RPA for the detection of S. japonicum in stool samples from 30 S. japonicum-infected patients and 30 healthy persons indicated 100% sensitivity and specificity. When testing 200 fecal or serum samples from a high-risk population, the percentage sensitivity of RPA was 100%, whereas that of indirect hemagglutination assay (IHA) and enzyme-linked immunosorbent assay (ELISA) were 80.3% and 85.2% respectively. In addition, the RPA presented better consistency with the stool-based tests than IHA and ELISA. Overall, the RPA was superior to other detection methods with respect to detection time, sensitivity, and convenience.Conclusions: This is the first time we applied the RPA technology to the field evaluation of S. japonicum infection. And the results suggest that RPA-based assays can be used as a promising point-of-care test for the diagnosis of schistosomiasis. [ABSTRACT FROM AUTHOR]

Background: Keratinocyte growth factor-2 (KGF-2) has been testified to be a multifunctional growth factor, which can stimulate the regeneration and reconstruction of epidermis, corium and mucosa. Its effect on Crohn's disease has hitherto not been evaluated. Here, we investigated the preventive and therapeutic actions of STEA, a mutant of human KGF-2 with high activity, on trinitrobenzene sulfonic acid (TNBS)-induced rat model of Crohn's disease., Methods: Rats with TNBS-induced colitis were treated with STEA and clinical scores were evaluated. Body weight, mortality, macroscopic and microscopic damage of the colonic tissue were examined. The levels of inflammatory cytokines in serum were detected by ELISA, the T cell subpopulations and the cell cycle of intestinal epithelial cells were analyzed by flow cytometry., Results: Both preventive and therapeutic administration of STEA significantly ameliorated body weight loss, diarrhea, and intestinal inflammation, reduced the high mortality and histopathologic damage of rats with TNBS-induced colitis. The serum level of inflammatory cytokines, such as TNF-α, IL-1β, IFN-γ and IL-6 were markedly decreased in colitis rats treated with STEA. The CD4+ and CD8+ T lymphocytes in peripheral blood were reduced with STEA administration at early stage of colitis. In addition, STEA treatment could promote the growth of intestinal epithelial cells by increasing the cell proportion in S phase of cell cycle and inhibiting cell apoptosis., Conclusions: Both preventive and therapeutic administration of STEA could ameliorate the colonic damages in rats with TNBS-induced colitis. STEA might be a promising option for the treatment of Crohn's disease.

Both interleukin-1 and IgE are important in the pathogenic mechanism of the allergy asthma. cDNA of interleukin-1receptor antagonist (IL-1ra) and IgE were cloned and a prokaryotic expression vector IL-1ra-Fcepsilon/pBV220 was constructed. The vector was transformed into Escherichia coli BL21(DE3). The fusion protein was expressed successfully in the form of inclusion body. The recombination protein of IL-1ra-Fcepsilon was highly purified by chromatography of gel filtration and ion exchange, which was identifited by Western blotting. The cell assay showed that the activity of IL-1ra-Fcepsilon was as high as IL-1ra in vitro after refolding. The pharmacokenetic profile of IL-1ra-Fcepsilon and L-1ra was analyzed, and the half time of IL-1ra-Fcepsilon is 4.78 times than that of IL-1ra.

The cDNA of Insulin-like growth factor binding protein 3 was subcloned into a eukaryotic secretory expression vector pSectagA to construct pSectag-IGFBP3. Human renal cell carcinoma (RCC) 786-0 cells were transfected with pSectag-IGFBP3 using lipofectamine 2000. After 48 h, the secretory IGFBP-3 was tested and identified by western blotting. Meanwhile, Annexin V-EGFP stain was used to analyze the apoptosis of 786-0 cells induced by IGFBP-3. Secretory IGFBP-3 protein could express successfully in the 786-0 cells and the expressed IGFBP-3 directly displayed an apoptotic effect on the host cells. This work provides a basis for further study on the apoptosis-inducing mechanism of IGFBP-3 and the development of a new anti-tumor drug.